Abstract library

3 results for "Feuilly".
#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial
Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Florence Marteau
#1860 Carcinoid Heart Disease (CHD): Prognostic Value of 5-HIAA and Impact on Survival – A Systematic Literature Review
Introduction: CHD is a life threatening complication of carcinoid syndrome. Its exact pathophysiology is uncertain but several studies have identified serotonin as a potential key mediator. The amount of serotonin production can be assessed by the dosage of its metabolite 5-HIAA in urine or plasma.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Marion Feuilly
Authors: Haig J, Kohli M, Pastor L, Feuilly M, ...
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster